Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.24
GSK's Cash to Debt is ranked lower than
83% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.33 vs. GSK: 0.24 )
Ranked among companies with meaningful Cash to Debt only.
GSK' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.46 Max: N/A
Current: 0.24
Equity to Asset 0.01
GSK's Equity to Asset is ranked lower than
97% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. GSK: 0.01 )
Ranked among companies with meaningful Equity to Asset only.
GSK' s Equity to Asset Range Over the Past 10 Years
Min: 0.01  Med: 0.24 Max: 0.4
Current: 0.01
0.01
0.4
Interest Coverage 1.92
GSK's Interest Coverage is ranked lower than
85% of the 475 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.69 vs. GSK: 1.92 )
Ranked among companies with meaningful Interest Coverage only.
GSK' s Interest Coverage Range Over the Past 10 Years
Min: 0.81  Med: 9.42 Max: 24.87
Current: 1.92
0.81
24.87
F-Score: 5
Z-Score: 1.17
M-Score: -2.63
WACC vs ROIC
9.19%
4.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 5.33
GSK's Operating margin (%) is ranked lower than
52% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.73 vs. GSK: 5.33 )
Ranked among companies with meaningful Operating margin (%) only.
GSK' s Operating margin (%) Range Over the Past 10 Years
Min: 1.68  Med: 28.24 Max: 34.91
Current: 5.33
1.68
34.91
Net-margin (%) 0.12
GSK's Net-margin (%) is ranked lower than
64% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.01 vs. GSK: 0.12 )
Ranked among companies with meaningful Net-margin (%) only.
GSK' s Net-margin (%) Range Over the Past 10 Years
Min: 5.76  Med: 19.43 Max: 23.2
Current: 0.12
5.76
23.2
ROE (%) 0.75
GSK's ROE (%) is ranked higher than
64% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.15 vs. GSK: 0.75 )
Ranked among companies with meaningful ROE (%) only.
GSK' s ROE (%) Range Over the Past 10 Years
Min: 17.3  Med: 61.93 Max: 84.89
Current: 0.75
17.3
84.89
ROA (%) 0.06
GSK's ROA (%) is ranked lower than
64% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.68 vs. GSK: 0.06 )
Ranked among companies with meaningful ROA (%) only.
GSK' s ROA (%) Range Over the Past 10 Years
Min: 3.84  Med: 13.20 Max: 20.43
Current: 0.06
3.84
20.43
ROC (Joel Greenblatt) (%) 14.14
GSK's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.13 vs. GSK: 14.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GSK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 40.79  Med: 85.34 Max: 107.42
Current: 14.14
40.79
107.42
Revenue Growth (3Y)(%) -4.00
GSK's Revenue Growth (3Y)(%) is ranked lower than
76% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. GSK: -4.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GSK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4  Med: 4.85 Max: 15.3
Current: -4
-4
15.3
EBITDA Growth (3Y)(%) -18.20
GSK's EBITDA Growth (3Y)(%) is ranked lower than
86% of the 553 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. GSK: -18.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GSK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.2  Med: 6.60 Max: 17.4
Current: -18.2
-18.2
17.4
EPS Growth (3Y)(%) -18.10
GSK's EPS Growth (3Y)(%) is ranked lower than
79% of the 510 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. GSK: -18.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GSK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.3  Med: 5.05 Max: 51.3
Current: -18.1
-30.3
51.3
» GSK's 10-Y Financials

Financials (Next Earnings Date: 2016-10-26)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

GSK Guru Trades in Q2 2015

Diamond Hill Capital 169,372 sh (+80.61%)
Jim Simons 3,246,100 sh (+24.25%)
John Rogers 1,214,427 sh (+16.22%)
Sarah Ketterer 507,631 sh (+15.47%)
NWQ Managers 510,500 sh (+11.86%)
Charles Brandes 4,313,622 sh (+11.20%)
Pioneer Investments 1,326,663 sh (+9.74%)
Jeff Auxier 146,482 sh (+8.38%)
Ken Fisher 11,533,371 sh (+7.22%)
Murray Stahl 23,823 sh (+0.21%)
Francis Chou 18,000 sh (unchged)
First Eagle Investment 1 sh (unchged)
Kahn Brothers 58,200 sh (unchged)
Louis Moore Bacon 100,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
PRIMECAP Management 4,595,385 sh (-0.06%)
Tweedy Browne 128,285 sh (-2.33%)
Joel Greenblatt 80,157 sh (-4.09%)
HOTCHKIS & WILEY 11,615,471 sh (-5.59%)
Barrow, Hanley, Mewhinney & Strauss 252,300 sh (-6.87%)
Dodge & Cox 12,476,998 sh (-46.76%)
» More
Q3 2015

GSK Guru Trades in Q3 2015

John Rogers 1,458,162 sh (+20.07%)
Sarah Ketterer 606,315 sh (+19.44%)
Charles Brandes 4,673,082 sh (+8.33%)
Murray Stahl 25,723 sh (+7.98%)
HOTCHKIS & WILEY 12,400,884 sh (+6.76%)
Tweedy Browne 133,458 sh (+4.03%)
Jeff Auxier 148,507 sh (+1.38%)
First Eagle Investment 1 sh (unchged)
Francis Chou 18,000 sh (unchged)
Diamond Hill Capital 169,372 sh (unchged)
NWQ Managers 82,800 sh (unchged)
Ken Fisher 11,528,069 sh (-0.05%)
Kahn Brothers 57,500 sh (-1.20%)
Barrow, Hanley, Mewhinney & Strauss 249,000 sh (-1.31%)
PRIMECAP Management 4,265,385 sh (-7.18%)
NWQ Managers 462,055 sh (-9.49%)
Joel Greenblatt 51,451 sh (-35.81%)
Jim Simons 1,430,600 sh (-55.93%)
Pioneer Investments 582,121 sh (-56.12%)
Dodge & Cox 202,915 sh (-98.37%)
» More
Q4 2015

GSK Guru Trades in Q4 2015

Steven Cohen 87,100 sh (New)
Kahn Brothers 84,600 sh (+47.13%)
Murray Stahl 26,348 sh (+2.43%)
NWQ Managers 469,830 sh (+1.68%)
John Rogers 1,476,976 sh (+1.29%)
Joel Greenblatt 51,973 sh (+1.01%)
Ken Fisher 11,531,673 sh (+0.03%)
Barrow, Hanley, Mewhinney & Strauss 249,000 sh (unchged)
Francis Chou 18,000 sh (unchged)
First Eagle Investment 1 sh (unchged)
Tweedy Browne 133,124 sh (-0.25%)
PRIMECAP Management 4,250,285 sh (-0.35%)
HOTCHKIS & WILEY 12,102,919 sh (-2.40%)
Pioneer Investments 551,520 sh (-5.26%)
Diamond Hill Capital 160,031 sh (-5.52%)
Charles Brandes 4,303,030 sh (-7.92%)
Jeff Auxier 136,032 sh (-8.40%)
Sarah Ketterer 518,275 sh (-14.52%)
Dodge & Cox 112,782 sh (-44.42%)
Jim Simons 176,400 sh (-87.67%)
» More
Q1 2016

GSK Guru Trades in Q1 2016

Jeremy Grantham 79,900 sh (New)
Lee Ainslie 28,520 sh (New)
Jim Simons 480,600 sh (+172.45%)
Kahn Brothers 131,950 sh (+55.97%)
John Rogers 1,582,913 sh (+7.17%)
NWQ Managers 498,115 sh (+6.02%)
Charles Brandes 4,474,409 sh (+3.98%)
Barrow, Hanley, Mewhinney & Strauss 251,800 sh (+1.12%)
Ken Fisher 11,657,855 sh (+1.09%)
First Eagle Investment 1 sh (unchged)
Pioneer Investments 551,520 sh (unchged)
Francis Chou 18,000 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt 51,331 sh (-1.24%)
Murray Stahl 25,973 sh (-1.42%)
Diamond Hill Capital 151,307 sh (-5.45%)
Tweedy Browne 116,070 sh (-12.81%)
Sarah Ketterer 450,405 sh (-13.10%)
Jeff Auxier 111,282 sh (-18.19%)
HOTCHKIS & WILEY 8,915,323 sh (-26.34%)
Dodge & Cox 81,262 sh (-27.95%)
PRIMECAP Management 1,116,885 sh (-73.72%)
» More
» Details

Insider Trades

Latest Guru Trades with GSK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:ABBV, NYSE:SNY, NYSE:LLY, OTCPK:BAYZF, NYSE:AZN, NYSE:BMY, NYSE:MRK, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:OPHLY, OTCPK:DSNKY, NYSE:NVS, OTCPK:KYKOF, OTCPK:SNPHF, OTCPK:CHJTF, OTCPK:PTKFF, OTCPK:MAYNF, OTCPK:GWPRF, NAS:HCM, AMEX:TXMD » details
Traded in other countries:GSK.Argentina, GS7.Germany, GSK N.Mexico, GSK.Switzerland, GSK.UK, GLAXF.USA,
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

GlaxoSmithKline PLC was incorporated on 6 December 1999 in the United Kingdom. The Company creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. Its principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led healthcare company that researches and develops products in three areas - pharmaceutical, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatrics and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. It has products in four main categories: Oral care, Nutritional, Total wellness, and Skin health. Its brands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.

Guru Investment Theses on GlaxoSmithKline PLC

Diamond Hill Capital Comments on GlaxoSmithKline PLC - Oct 17, 2014

We eliminated our position in GlaxoSmithKline PLC (GSK) due to concerns that the company will not be able to preserve the recent level of revenue or profitability generated by its respiratory franchise. Despite its development of high efficacy next generation respiratory drugs that have come to market in advance of Advair losing patent protection, the company is facing extreme pricing pressure from health care payors. Diversified machinery manufacturer Dover Corp. was eliminated as the stock price approached our estimate of intrinsic value.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about GlaxoSmithKline PLC

Kahn Brothers Adds to BP, GlaxoSmithKline Stakes Firm founded by Irving Kahn adds to 8 holdings
Legendary investor Irving Kahn, along with his brothers Thomas Graham and Alan Kahn, founded the Kahn Brothers (Trades, Portfolio) Group in 1978, an investment firm that manages more than $800 million in assets. Irving Kahn trained directly with Benjamin Graham and served as his teaching assistant at Columbia Business School. Read more...
Dodge & Cox Sells Most of Stakes in Chevron, GlaxoSmithKline Guru invests in stakes in UBS Group, Harley-Davidson
A team research approach guides Dodge & Cox’s investment decisions. The strategy works pretty well. Dodge & Cox enjoyed returns of more than 10% in 2014, which was good compared to many investors but modes compared to the returns from 2012 (22.01%) and 2013 (40.55%). Read more...

Ratios

vs
industry
vs
history
Forward P/E 19.08
GSK's Forward P/E is ranked lower than
59% of the 81 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. GSK: 19.08 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 27.90
GSK's Price/Owner Earnings (ttm) is ranked lower than
52% of the 282 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.57 vs. GSK: 27.90 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GSK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.81  Med: 16.41 Max: 45.91
Current: 27.9
4.81
45.91
P/B 143.05
GSK's P/B is ranked lower than
99% of the 823 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. GSK: 143.05 )
Ranked among companies with meaningful P/B only.
GSK' s P/B Range Over the Past 10 Years
Min: 5.48  Med: 9.29 Max: 143.05
Current: 143.05
5.48
143.05
P/S 3.27
GSK's P/S is ranked lower than
56% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. GSK: 3.27 )
Ranked among companies with meaningful P/S only.
GSK' s P/S Range Over the Past 10 Years
Min: 1.94  Med: 2.80 Max: 4.22
Current: 3.27
1.94
4.22
PFCF 54.81
GSK's PFCF is ranked lower than
93% of the 221 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.52 vs. GSK: 54.81 )
Ranked among companies with meaningful PFCF only.
GSK' s PFCF Range Over the Past 10 Years
Min: 8.24  Med: 16.88 Max: 135.68
Current: 54.81
8.24
135.68
POCF 22.12
GSK's POCF is ranked lower than
70% of the 292 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.35 vs. GSK: 22.12 )
Ranked among companies with meaningful POCF only.
GSK' s POCF Range Over the Past 10 Years
Min: 6.61  Med: 12.37 Max: 27.31
Current: 22.12
6.61
27.31
EV-to-EBIT 72.87
GSK's EV-to-EBIT is ranked lower than
85% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.71 vs. GSK: 72.87 )
Ranked among companies with meaningful EV-to-EBIT only.
GSK' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 10.60 Max: 72.3
Current: 72.87
6.3
72.3
EV-to-EBITDA 35.34
GSK's EV-to-EBITDA is ranked lower than
69% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.97 vs. GSK: 35.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
GSK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 9.10 Max: 35.1
Current: 35.34
5.6
35.1
Shiller P/E 17.46
GSK's Shiller P/E is ranked higher than
88% of the 151 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 50.39 vs. GSK: 17.46 )
Ranked among companies with meaningful Shiller P/E only.
GSK' s Shiller P/E Range Over the Past 10 Years
Min: 11.71  Med: 14.95 Max: 20.67
Current: 17.46
11.71
20.67
Current Ratio 0.93
GSK's Current Ratio is ranked lower than
84% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. GSK: 0.93 )
Ranked among companies with meaningful Current Ratio only.
GSK' s Current Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.27 Max: 1.78
Current: 0.93
0.93
1.78
Quick Ratio 0.63
GSK's Quick Ratio is ranked lower than
86% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. GSK: 0.63 )
Ranked among companies with meaningful Quick Ratio only.
GSK' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 0.99 Max: 1.42
Current: 0.63
0.63
1.42
Days Inventory 202.72
GSK's Days Inventory is ranked lower than
82% of the 666 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.20 vs. GSK: 202.72 )
Ranked among companies with meaningful Days Inventory only.
GSK' s Days Inventory Range Over the Past 10 Years
Min: 167.28  Med: 190.92 Max: 202.64
Current: 202.72
167.28
202.64
Days Sales Outstanding 86.98
GSK's Days Sales Outstanding is ranked lower than
60% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.90 vs. GSK: 86.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
GSK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.62  Med: 74.32 Max: 93.9
Current: 86.98
54.62
93.9

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.06
GSK's Dividend Yield is ranked higher than
95% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. GSK: 5.06 )
Ranked among companies with meaningful Dividend Yield only.
GSK' s Dividend Yield Range Over the Past 10 Years
Min: 2.72  Med: 5.09 Max: 6.24
Current: 5.06
2.72
6.24
Dividend Growth (3y) 1.90
GSK's Dividend Growth (3y) is ranked lower than
64% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. GSK: 1.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
GSK' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -12.6  Med: 7.00 Max: 20.8
Current: 1.9
-12.6
20.8
Forward Dividend Yield 4.89
GSK's Forward Dividend Yield is ranked higher than
95% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. GSK: 4.89 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 7.00
GSK's Yield on cost (5-Year) is ranked higher than
93% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.93 vs. GSK: 7.00 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GSK' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.76  Med: 7.04 Max: 8.63
Current: 7
3.76
8.63
3-Year Average Share Buyback Ratio -2.00
GSK's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. GSK: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GSK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.3  Med: 1.20 Max: 4.7
Current: -2
-20.3
4.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.60
GSK's Price/Projected FCF is ranked higher than
54% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. GSK: 2.60 )
Ranked among companies with meaningful Price/Projected FCF only.
GSK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.97  Med: 1.61 Max: 21.79
Current: 2.6
0.97
21.79
Price/Median PS Value 1.17
GSK's Price/Median PS Value is ranked lower than
53% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. GSK: 1.17 )
Ranked among companies with meaningful Price/Median PS Value only.
GSK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.71  Med: 1.17 Max: 3.34
Current: 1.17
0.71
3.34
Earnings Yield (Greenblatt) (%) 1.40
GSK's Earnings Yield (Greenblatt) (%) is ranked lower than
59% of the 844 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. GSK: 1.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GSK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.4  Med: 9.50 Max: 15.8
Current: 1.4
1.4
15.8
Forward Rate of Return (Yacktman) (%) -0.03
GSK's Forward Rate of Return (Yacktman) (%) is ranked higher than
53% of the 325 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. GSK: -0.03 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
GSK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.1  Med: 12.60 Max: 34.6
Current: -0.03
0.1
34.6

More Statistics

Revenue (TTM) (Mil) $36,959
EPS (TTM) $ 0.01
Beta0.96
Short Percentage of Float0.24%
52-Week Range $37.24 - 45.49
Shares Outstanding (Mil)2,436.20

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 33,292 34,616 36,298
EPS ($) 2.44 2.54 2.55
EPS w/o NRI ($) 2.44 2.54 2.55
EPS Growth Rate
(3Y to 5Y Estimate)
2.51%
Dividends Per Share ($) 2.27 2.16 2.16
» More Articles for GSK

Headlines

Articles On GuruFocus.com
GlaxoSmithKline’s Sideways Dance May Pay Off in the Long Run Jul 22 2016 
Why Berkshire Hathaway Dumped Johnson & Johnson Jul 19 2016 
Andreas Halvorsen's Viking Global Gets Control of Stakes in 2 Companies for Backing Hot Biotech Jul 14 2016 
Investing in Big Pharma: Pointers on Pfizer Jul 14 2016 
Getting to Know VBI Vaccines Jul 13 2016 
Jeff Auxier Sells Precision Castparts, AT&T, Microsoft Jun 23 2016 
Steven Cohen Adds to Stake in Pernix Therapeutics Jun 07 2016 
PhaseRX: The Latest Pick From a Legendary VC Firm May 24 2016 
Kahn Brothers Adds to BP, GlaxoSmithKline Stakes May 10 2016 
A Closer Look Into Veritas Pharma Apr 21 2016 

More From Other Websites
Veeva Provides The Software In Big Pharma's Race Against The Clock Jul 29 2016
Brexit: GlaxoSmithKline Invests $361M in the UK (GSK) Jul 29 2016
Director/PDMR Shareholding Jul 28 2016
Glaxo (GSK) Beats Q2 Earnings Estimates, Revenues Up Y/Y Jul 28 2016
AstraZeneca Earnings, Sales Edge Above Forecasts Jul 28 2016
[$$] GlaxoSmithKline Helped and Hurt by Sterling’s Post-Brexit Fall Jul 27 2016
[$$] GlaxoSmithKline Helped and Hurt by Sterling's Post-Brexit Fall Jul 27 2016
GSK Plans £275m UK Investment After EU Vote Jul 27 2016
Why Fiat Chrysler, Coca-Cola, Anthem and 2 Other Stocks Are Moving Today Jul 27 2016
4 Surprising Quality Growth Stocks That Pay at Least a 5% Dividend Jul 27 2016
McDonald’s Joins Glaxo in Giving Jobs Boost to Post-Brexit U.K. Jul 27 2016
Stocks Rise At Open As Apple Hauls Techs Higher Jul 27 2016
GSK invests $A481m in post-Brexit UK Jul 27 2016
GlaxoSmithKline invests $360 million in UK despite Brexit Jul 27 2016
GlaxoSmithKline invests 275 million pounds in UK despite Brexit Jul 27 2016
GlaxoSmithKline invests $360 mln in UK despite Brexit Jul 27 2016
Glaxo reports 2Q loss Jul 27 2016
Glaxo reports 2Q loss Jul 27 2016
GlaxoSmithKline CEO on Performance, Products, Growth Jul 27 2016
GlaxoSmithKline CEO: Strong Currency Tailwind Effect Jul 27 2016
Should you buy GlaxoSmithKline plc after today’s results? Jul 27 2016
Glaxo (GSK) Beats Q2 Earnings, Revenues Rise Y/Y Jul 27 2016
GSK CEO on Brexit Jul 27 2016
GlaxoSmithKline Rallies on Strong Quarterly Results Jul 27 2016
GSK results ride sterling's roller-coaster Jul 27 2016
UK drugs giant GSK invests £275 mn despite Brexit Jul 27 2016
Should You Buy GlaxoSmithKline After Today's Brilliant Results? Jul 27 2016
GSK chases next biotech asthma drug with 175 million pounds J&J deal Jul 27 2016
GSK outlook brightens as Brexit brings currency windfall Jul 27 2016
GSK outlook brightens as Brexit brings currency windfall Jul 27 2016
GSK outlook brightens as Brexit brings currency windfall Jul 27 2016
Glaxo’s Earnings Beat Estimates as New Product Sales Double Jul 27 2016
GSK chases next biotech asthma drug with $230 mln J&J deal Jul 27 2016
GSK chases next biotech asthma drug with $230 mln J&J deal Jul 27 2016
GlaxoSmithKline invests $360 mln in post-Brexit UK manufacturing Jul 27 2016
UK drugs giant GSK invests £275 mn despite Brexit Jul 26 2016
Director/PDMR Shareholding Jul 25 2016
Your inhaler's watching you: drugmakers race for smart devices Jul 20 2016
Your inhaler's watching you: drugmakers race for smart devices Jul 20 2016
Novartis in no rush to sell down stake on GSK consumer venture Jul 19 2016
Novartis in no rush to sell down stake on GSK consumer venture Jul 19 2016
Will GlaxoSmithKline plc and AstraZeneca plc continue to be Brexit winners? Jul 19 2016
Director/PDMR Shareholding Jul 18 2016
These 5 FTSE 100 stars are looking far too cheap! Jul 18 2016
Price Monitoring Extension Jul 14 2016
Second Price Monitoring Extn Jul 14 2016
BUZZ-GSK dividend looks safe post-Brexit, even with new CEO Jul 14 2016
Grab this 5% yield while you still can! Jul 14 2016
Director/PDMR Shareholding Jul 12 2016
Even after recent gains, GlaxoSmithKline plc may still be undervalued! Jul 12 2016
ARM Holdings plc, GlaxoSmithKline plc and Greggs plc: 3 of the safest dividends for ‘Brexit... Jul 08 2016
Drug industry CEOs lead new task force on Brexit's pharma fallout Jul 07 2016
Drug industry CEOs lead new task force on Brexit's pharma fallout Jul 07 2016
Brace yourself for interest rate cuts with GlaxoSmithKline plc, National Grid plc and BAE Systems... Jul 07 2016
Director/PDMR Shareholding Jul 01 2016
Total Voting Rights Jul 01 2016
Are GlaxoSmithKline plc, Trinity Mirror plc and DJI Holdings plc today’s best post-Brexit buys? Jul 01 2016
Are dividends from Royal Dutch Shell (6.7%), Legal & General (8%) and GlaxoSmithKline (5.5%) now... Jun 30 2016
Limited protection of GSK's malaria vaccine dwindles in 7 years Jun 29 2016
FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort®... Jun 20 2016
FULFIL Study Results Closed Triple EU Jun 20 2016
Directorate Change Jun 14 2016
Director/PDMR Shareholding Jun 10 2016
GSK announces phase III study of sirukumab meets both co-primary endpoints in patients with... Jun 08 2016
Phase III Study of Sirukumab Results Jun 08 2016
U.S. top court rejects GSK bid to throw out racketeering lawsuits Jun 06 2016
In fight for GSK's Advair, generic firms step carefully on price Jun 03 2016
In fight for GSK's Advair, generic firms step carefully on price Jun 03 2016
Closed Triple Combined FF-UMEC-VI US Filing Plans Jun 02 2016
Anti-graft group says drugmakers failing to tackle corruption Jun 01 2016
Anti-graft group says drugmakers failing to tackle corruption Jun 01 2016
Regulus Expands Clinical Trial Collaboration with GSK Jun 01 2016
Total Voting Rights Jun 01 2016
GSK gets EU approval for first gene therapy for children May 27 2016
GSK gets EU approval for first gene therapy for children May 27 2016
StrimvelisTM receives European marketing authorisation to treat very rare disease, ADA-SCID May 27 2016
Ionis shares plummet as GSK scraps heart drug trial plans May 26 2016
GSK lung drug succeeds in big UK study, after earlier miss May 24 2016
EU lifts suicide warning on Pfizer's smoking-cessation pill May 23 2016
UK drugs watchdog warns it will struggle if Britain leaves EU May 23 2016
UK cost body finally approves limited use of GSK's lupus drug May 10 2016
GSK chairman rules out near-term break-up of drugmaker May 05 2016
Advocates hold NYC protest over price of pneumonia vaccine Apr 27 2016
GSK finds axing doctor payments needn't torpedo sales Apr 27 2016
GSK sees rise in sales of vaccines, healthcare products Apr 27 2016
GlaxoSmithKline promises reduced drug patents to help world's poor Mar 31 2016
GlaxoSmithKline CEO Witty to bow out in March 2017 Mar 17 2016
GSK dismisses near-term split as new drugs offset falling Advair Feb 03 2016
Five charged in U.S. with stealing secrets from GlaxoSmithKline Jan 21 2016
Amgen reacquires rights to three drugs from Glaxo in 48 countries Dec 14 2015
GSK plan to file up to 20 new drugs by 2020 underwhelms market Nov 03 2015
GlaxoSmithKline net dips 26 percent in Q2 Oct 31 2015
GlaxoSmithKline beats forecasts as HIV drugs, flu vaccines shine Oct 28 2015
Analysis of GSK's Seroxat antidepressant finds key data was held back Sep 16 2015
Exclusive - GSK faces new corruption allegations, this time in Romania Jul 29 2015
GlaxoSmithKline beats profit forecasts despite Advair hit, lower margins Jul 29 2015
GSK scraps plan to list HIV drugs business and shields dividend May 06 2015
Interview - New-look GSK bets on consumer health spending May 06 2015
Doubts grow over GlaxoSmithKline's $6 bln capital return plan May 01 2015
GSK gets a lift as Express Scripts reinstates lung drug Advair Aug 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)